Iterum Therapeutics Reports Fourth Quarter and Full Year 202

--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r

Related Keywords

United States , Dublin , Ireland , Chicago , Illinois , Judy Matthews , Corey Fishman , Drug Administration , Nasdaq , Recourse Royalty , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Exchangeable Senior Subordinated Notes , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Financial Officer , Consolidated Statement ,